- Home
- OKYO vs IMA Comparison
OKYO vs IMA Comparison
Compare OKYO & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$2.76
N/A
Current Price
$6.94
Company Overview
Basic Information| Metric | OKYO | IMA |
|---|---|---|
| Founded | 2007 | 2019 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.7M | 65.4M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | OKYO | IMA |
|---|---|---|
| Price | $2.76 | $6.94 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 2 |
| Target Price | $6.00 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 129.2K | 63.2K |
| Earning Date | 07-18-2025 | 02-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.90 | $5.70 |
| 52 Week High | $3.35 | $18.00 |
Technical Indicators
Market Signals| Indicator | OKYO | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 67.19 | N/A |
| Support Level | $1.90 | N/A |
| Resistance Level | $2.48 | N/A |
| Average True Range (ATR) | 0.20 | 0.00 |
| MACD | 0.07 | 0.00 |
| Stochastic Oscillator | 90.99 | 0.00 |
Price Performance
Historical Comparison OKYO
IMA
About OKYO OKYO Pharma Limited
OKYO Pharma Ltd is a biopharmaceutical company. The company is developing therapeutics to improve the lives of patients with inflammatory eye diseases and chronic pain. It offers solutions for various diseases such as Dry Eye Disease, Non-infectious Anterior Uveitis, Allergenic Conjunctivitis, Chronic Pain, and Ocular Pain.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.